ReviewFrontiers in molecular biosciences2026
Exosomal microRNAs as biomarkers of multimorbidity risk in lean and obese women with polycystic ovary syndrome.
Review in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovarian syndrome (PCOS) is a multifactorial endocrine disorder that is characterised by reproductive, metabolic and cardiometabolic abnormalities. Besides typical hormonal abnormalities, inter-organ communication has a crucial role in the development of PCOS-associated multimorbidity. PCOS causes early changes in the insulin signalling pathway, inflammatory pathways, androgen synthesis genes, and ovarian theca cell activity even before the appearance of regular symptoms such as irregular periods, polycystic ovaries, weight gain, and hyperandrogenism. Exosomes are tiny extracellular vesicles discharged into the circulation. It transports molecular cargoes such as microRNAs (miRNAs), proteins that influence gene expression and reflect the underlying pathophysiological condition of target tissues. Exosomes facilitate early disease detection by carrying stable, selectively packaged gene-regulatory molecules that reflect early cellular and molecular alterations before phenotypic manifestations occur. Although exosomal miRNAs (ExomiR) are stable, non-invasive, and easily detectable in body fluids, they serve as a potent biomarkers. These circulating ExomiR have contributed to multiple organ dysfunctions, including the ovary, adipose tissue, liver, cardiovascular system, and brain, thereby raising the risk of comorbid conditions like endometrial disorder, insulin resistance, type 2 diabetes, non-alcoholic fatty liver disease, and cardiovascular disease. In obese PCOS, circulating ExomiR influences pathways related to steroidogenesis, insulin signalling, inflammation, oxidative stress, and lipolysis. However, its role in lean PCOS is not well studied. This review summarises the potential roles of ExomiR as novel biomarkers that bridge reproductive and non-reproductive facets of PCOS, indicating new paths for precision medicine and tailored treatment interventions in both lean and obese PCOS phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.